Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Stopped early · Phase 2

Conditions studied: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases

In brief

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with high-risk leukemia.

Key facts

Study ID

NCT00066417

Run by

National Heart, Lung, and Blood Institute (NHLBI)

People needed

51

Expected to finish

2007-01-01

Last updated by the study team

2013-05-01

Who can join

Age: 10 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NIH - Warren Grant Magnuson Clinical Center — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.